EFS-SaCas9 AAV (Serotype 9)

The EFS-SaCas9 AAV (adeno-associated viral vector) serotype 9 is an advanced tool that leverages the powerful CRISPR/Cas9 technology to achieve precise genome editing. Designed for efficient gene delivery, these pre-made AAV particles express the Staphylococcus aureus Cas9 (SaCas9) enzyme and integrate seamlessly into a viral vector using its compact size. The SaCas9 is expressed under the control of the EFS promoter, which is known for its stable expression in a variety of cell types, thus enhancing the utility of this vector in different biological studies. The serotype 9 designation of these AAV particles indicates its specific viral capsid, which preferentially binds to certain cell surface receptors, thereby directing the virus to specific tissues or cell types. Serotype 9 AAV is particularly known for its efficient transduction of muscle, liver, and central nervous system cells, making it an excellent choice for research in these areas. Its ability to cross the blood-brain barrier enhances its appeal in neurological research, expanding the possibilities for studying and potentially treating diseases such as muscular dystrophy, liver disease, and neurodegenerative diseases. The smaller size of SaCas9 relative to the more commonly used SpCas9 allows it to be easily adapted to the packaging capacity of AAV, allowing for the addition of additional guide RNAs or regulatory elements within the same vector. This flexibility is critical for performing complex genome engineering tasks within strict size constraints.